Brain Cancer

Metastatic Breast Cancer

Breast Cancer

Colorectal Cancer

Gastric Cancers

Liver Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancer

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head and Neck Cancers

Graft-Vs-Host Disease

Leukemia

Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Hematology

Lung Cancer

Pediatric Cancer

Sarcomas

Melanoma

Skin Cancer

Adding E-602 to cemiplimab demonstrated anti-tumor effects in patients PD-L1–resistant solid cancers. 

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers

Mitazalimab combined with mFOLFIRINOX led to responses and survival benefits in patients with metastatic pancreatic ductal adenocarcinoma. 

Mitazalimab Plus mFOLFIRINOX Improves Survival in Pancreatic Cancer

The novel drug SHR-A1921 was safe and efficacious in patients with platinum-resistant ovarian cancer, according to phase 1 data. 

Novel ADC Shows Promise in Platinum-Resistant Ovarian Cancer

Docetaxel was associated with lower rates of peripheral neuropathy compared with paclitaxel for Black patients with breast cancer. 

Chemo Should be Tailored to Decrease Neuropathy in Black Patients

News

Latest News

FDA News

Adverse Event Management

Supportive Care

Disparities in Cancer Care

Drug Safety

Radiation Oncology

Survivorship 

Practice Management

Prevention

Contributors

Media

Expert Connections

Morning Rounds

The Vitals

Podcasts

Videos

Between the Lines

Meeting of the Minds

Training Academy

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Continuing Education

Resources

Case-Based Digest 

Rx Road Map

Webinars

Cancer Summary Slides

MPN Symptom Management

Events

Subscribe

Partners

Articles

The phase 3 KEYNOTE-826 trial met its dual primary end points of overall and progression-free survival in patients with cervical cancer.

Addition of Pembrolizumab to Chemo Improves Survival in Cervical Cancer

Amanda Brink is a nurse practitioner at the University of Texas MD Anderson Cancer Center. When she is not tending to patients in the hospital or clinic, she finds great satisfaction in crafting content to enlighten the public and her fellow nurses about a range of health topics.

Oncology nurses can educate patients about the potential indications for oncolytic virus therapy and connect them to available clinical trial opportunities.

Opinion: A Case of Self-Experimentation with Oncolytic Virus Therapy Highlights the Need for More Research

Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Lenvatinib showed a median PFS of 5.4 months in advanced HCC patients following treatment with atezolizumab/bevacizumab, meeting the primary endpoint.

Second-Line Lenvatinib Shows Promising PFS in Advanced HCC

Niraparib plus dostarlimab with platinum-based chemotherapy achieved superior PFS, meeting the primary end point of the phase 3 FIRST-ENGOT-OV44 trial. 

Addition of Niraparib/Dostarlimab Improves PFS in Advanced Ovarian Cancer

CancerNetwork.com

CureToday.com

OncLive.com

TargetedOnc.com

Advertise

Privacy

Terms & Conditions

Do Not Sell My Information

Oncology Nursing News

Facebook

LinkedIn

Specialty

Advanced Practice Providers

Clinical

Gynecologic Cancer

Immunotherapy

Nurse Navigation

Quality Improvement

Sap Partners

Is your organization missing from this list? Reach out to Danielle Cann, Strategic Alliance Partnership Coordinator, to learn more about the complimentary strategic partnership program: 

1rem

Strategic Alliance Partners

The University of South Alabama, Mitchell Cancer Institute

The University of South Alabama, Mitchell Cancer Institute | Strategic Alliance Partners

Latest from The University of South Alabama, Mitchell Cancer Institute

Latest Conference Coverage